Sensible Medical Innovations Closes on Financing Round Led by Boston Scientific Corporation

Share Article

Proceeds are Intended to Be Used for Further Collection of Clinical Data and Global Product Commercialization

Sensible Medical Innovations (Sensible), the developer of a non-invasive thoracic fluid status monitor, today announced the closing of its latest round of funding. The round was led by Boston Scientific Corporation (NYSE: BSX) and joined by Shanghai LongTec Medical Technology Co., Ltd. and current investors SCP Vitalife and Genesis Partners. Proceeds are intended to be used for further collection of clinical data and global product commercialization.

Sensible’s disruptive, non-invasive technology provides a quantitative absolute measurement of lung fluid content and is intended for patients with fluid management problems such as patients living with heart failure, patients taking diuretic medication, recovering from a coronary artery disease related event or living with end stage renal disease.

The Sensible solution is designed to enable patients and physicians to monitor patients’ lung fluid more precisely than the weight- and symptoms-based monitoring used today. In addition, the non-invasive, wearable device does not require patients to undergo the surgery required with more invasive implantable hemodynamic monitors. Effective lung fluid status management is intended to improve the quality of care while reducing the overall cost related to hospitalizations.

“Having worked with Sensible for the past few years, I am impressed with the data demonstrating the technology’s performance, accuracy and robustness,” said Professor William T. Abraham, Director of Cardiovascular Medicine at The Ohio State University Wexner Medical Center and Chairman of Sensible’s Physician Steering Committee. “The need for an absolute measurement of lung fluid is critical and will enable us to take better care of our patients.”

“Current data provide promising evidence that the device can be used as an effective tool to improve patient care and outcomes in a disease that still has high mortality rates and significant costs to society,” said Professor Stefan Anker, President of the Heart Failure Association of the European Society of Cardiology and a member of Sensible’s Physician Steering Committee. “This non-invasive technology appears well suited for medical needs in Europe.”

“We are humbled and excited to join forces with our new investors whose funding will help bring the company to the next level,” said Amir Ronen, CEO of Sensible. “We are proud that our technology has been embraced by leading physicians worldwide who are helping us in our path towards commercialization. A robust and accurate technology for non-invasive fluid monitoring is clearly a dramatic and disruptive capability that could impact the lives of millions.”

About Sensible Medical Innovations
Sensible has developed a wearable thoracic fluid status monitor for non-invasive monitoring and management of patients with fluid management problems such as patients living with heart failure, taking diuretic medication, recovering from a coronary artery disease related event and patients living with end stage renal disease. The company, headquartered in Kfar Neter, Israel was founded in 2007, by Amir Ronen, Amir Saroka, Dan Rappaport, Nadav Mizrahi and Shlomi Bergida.

Media Contact
Ido Atiya
Tell: + 972-3-6880908
Cell: +972-54-4289205

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Ido Atiya

+972 544289205
Email >